LBA21 KEYNOTE-756: Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+/HER2– breast cancer
Year: 2023
Type: article
Source: Annals of Oncology
Institutions: Champalimaud Foundation, Centro Champalimaud, The University of Texas Southwestern Medical Center, Queen Mary University of London, Barts Cancer Institute, IDCQ Hospitales y Sanidad, S.L.U., Universidad Europea de Madrid, LMU Klinikum, Ludwig-Maximilians-Universität München, Stanford Medicine, Stanford University, Princess Margaret Cancer Centre, Baylor University Medical Center, The US Oncology Network, Universitätsklinikum Erlangen, Comprehensive Cancer Center Erlangen, Shanghai Medical College of Fudan University, Fudan University, Fudan University Shanghai Cancer Center, Institut Curie, Samsung Medical Center, Sungkyunkwan University, Zhengzhou University, Henan Cancer Hospital, Osaka National Hospital, Merck & Co., Inc., Rahway, NJ, USA (United States), Harvard University, Massachusetts General Hospital
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: bronze
OpenAlex ID: W4387809682
